 SOUTH SAN FRANCISCO, Calif.BUSINESS WIREGenentech, a member of the Roche Group SIX: RO, ROG; OTCQX: RHHBY, today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival RFS at the prespecified interim analysis. The study is evaluating Tecentriq atezolizumab in combination with Avastin bevacizumab as adjuvant treatment following surgery for people ... Genentechs Tecentriq Plus Avastin Is the First Treatment Co... 